Dr. Mark Pegram & Dr. Ana Garrido-Castro – Breakthrough Data in Metastatic TNBC

At ESMO Berlin, Dr. Mark Pegram and Dr. Ana Garrido-Castro break down breakthrough data shaping the new standard for first-line metastatic triple-negative breast cancer (TNBC).

Together, they unpack results from ASCENT-03 and TROPION-Breast02, where Trop-2 antibody-drug conjugates demonstrated significant improvements in response rates, PFS, and — in one study — overall survival.

Drs. Pegram and Garrido-Castro explore:
• Why Trop-2 ADCs may replace chemotherapy in PD-L1–negative TNBC
• Key differences in trial design, patient selection, and endpoints
• Real-world decision-making based on toxicity, dosing schedules, and prophylaxis
• How HR-low disease, BRCA/PALB2 status, and CNS involvement factor into treatment strategy

A must-listen for clinicians navigating the fast-evolving landscape of metastatic TNBC and the rise of ADC-driven precision therapy.